Immunohistochemistry
Customize your policy alerts
Sign up for avalon_healthcare_solutions Policy AHS alerts
Get alerted when Policy AHS changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage, coding, and clinical context for immunohistochemistry and multiplex immunohistochemistry procedures used to identify tissue/cellular antigens for diagnosis and treatment decisions; it applies to providers submitting claims to Avalon Healthcare Solutions.
No material clinical or coverage changes in this revision.
Coverage Criteria
General coverage
Covered when clinical use and coding align with standard diagnostic purposes and coding rules stated below.
See Clinical Validity and Utility and coding limits below.
Discussion of a test's regulatory status (for example, whether an assay is listed in the FDA device database or performed as a laboratory-developed test) does not by itself determine coverage. FDA clearance/approval is not required for clinical use of LDTs, and LDTs are regulated under CLIA as high-complexity tests; therefore regulatory descriptions in this policy should not be construed as automatic exclusions from coverage.
A targeted literature review and subsequent revision history entries updated background materials and references but did not require changes to the policy's coverage criteria. No new exclusions or coverage additions were recorded as a result of the review.
Supplemental criteria or inventory notes: no additional coverage criteria or exclusions are recorded in this section beyond those summarized elsewhere in the policy.
Covered Indications
Diagnostic evaluation, therapy selection, infectious detection, and Lynch syndrome screening
Covered when used for diagnostic evaluation of tumors, selection of therapy, detection of infectious organisms, or tumor screening as specified below.
Supported by Clinical Validity and Utility and referenced guideline literature.
Consistent with NCCN and ASCO/CAP guideline recommendations.
Clinical uses described in Clinical Validity and Utility.
NCCN recommends tumor testing with IHC and/or MSI for MMR proteins in CRC.
Billing beyond these unit limits may trigger payment denial or adjustment.
Diagnostic and predictive use of IHC supported by literature and guidelines
Covered when the diagnostic or predictive use of IHC is supported by cited literature and clinical guidelines for the tumor type or clinical question.
References: NCCN, ASCO/CAP guideline updates (Wolff et al.).
Supported by cited systematic reviews and methodological references.
Supported by methodological and validation studies cited in Evidence-based Scientific References.
References include listed evidence-based scientific references and NCCN guidelines.
Applicable CPT/HCPCS and Coding Rules
| 88341 | Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure. |
| 88342 | Immunohistochemistry or immunocytochemistry, per spec; initial single antibody stain. |
| 88344 | Immunohistochemistry or immunocytochemistry, per specimen; each multiplex antibody stain procedure. |
Provider Actions and Billing Rules
IHC coding and unit limits — follow CPT and unit rules
Code and unit reimbursement rules for immunohistochemistry must be followed: use 88342 for the first single antibody procedure (reimbursed at one unit per specimen, up to four specimens per date of service), 88341 for each additional single antibody per specimen (reimbursed up to a maximum of 13 units per date of service), and 88344 for each multiplex antibody per specimen (up to six specimens per date of service).
Prior authorization status unchanged after literature review
Prior authorization and the policy's coverage criteria remain unchanged after the literature review; there were no modifications to prior authorization or coverage criteria documented during the update.
Provider documentation and billing preparedness
Ensure coding, documentation, and billing adhere to the policy limits and guidance above; retain specimen-level documentation to support units billed and readiness to supply plan-specific authorization if requested.
- Maintain specimen counts and antibody type documentation per specimen and date of service to support CPT code selection and units billed
- Be prepared to reference the plan contract (Evidence of Coverage) if authorization/payment conflicts arise
No step therapy requirements specified
No step therapy requirements are specified in the provided sections of this policy.
Coding and documentation requirements — use 88342 / 88341 / 88344 as specified
Use CPT code 88342 for the first single antibody stain per specimen, CPT 88341 for each additional single antibody stain per specimen, and CPT 88344 for each multiplex antibody stain per specimen; documentation should support specimen counts and antibody types per specimen and date of service.
Revision history — evidence/guidelines updated without coverage changes
Revision history records updates to background, guidelines, and evidence-based references but did not change coverage criteria; note the 05/23/2022 update that refreshed evidence references.
- 01/01/2022: Initial Effective Date
- 05/23/2022: Updated background, guidelines, and evidence-based scientific references; literature review did not change coverage criteria
Literature review did not change coverage criteria (provider affirmation)
The literature review concluded that no modifications to the coverage criteria were necessary; providers may rely on existing coverage rules and coding limits as documented.
Frequency and Unit Limits
Ordering Requirements
Coverage depends on member benefits at time of request
Coverage depends on the individual's benefit coverage at the time of request; the Medical Policy Statement does not guarantee authorization or payment and the plan contract (Evidence of Coverage) governs determinations.
- Verify member benefit coverage and Evidence of Coverage prior to ordering
- Policy statements do not ensure authorization or payment
Who may order testing not specified
The policy sections provided do not specify which provider types may order testing.
Not Covered
No explicit tests or clinical indications are listed as not covered in the provided sections of this policy. Statements about FDA status or LDT validation do not by themselves constitute a denial of coverage.
Review of the provided policy sections did not identify any specific tests or indications that are explicitly excluded from coverage; the revision history confirms the literature review did not produce exclusions.
Definitions
Background
Immunohistochemistry (IHC) is a staining technique that uses antibodies to detect specific target antigens in tissue or cell preparations. The antibody binds the target antigen and a biochemical label or tag creates a visual signal to identify cells, tissue components, or organisms.
IHC is applied for diagnostic purposes such as tumor classification, determining tumor origin, assessing markers used for prognosis and treatment selection (for example, ER/PR/HER2 in breast cancer), and for detecting infectious organisms. Multiplex IHC (mIHC) expands this approach by detecting multiple targets simultaneously in a single tissue section to characterize the tumor microenvironment and inform therapeutic decisions.
Revision History
Initial effective date recorded for the Immunohistochemistry policy.
Policy underwent literature review and updates to background, guidelines, and evidence references without changes to coverage criteria.
Policy document version with updated evidence references published with effective date 2022-10-01; no modifications to coverage criteria were required following the review.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.